Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.
This gives us the potential to revolutionise how people think about brain health.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Supporting patient care
- Helping clinicans in their diagnosis
- Differential patterns of brain changes
- Accurately tracking changes
- Proactive brain health
Latest news
Oxford Brain Diagnostics to Provide MRI-based Metrics for NeuroTherapia's Alzheimer's Phase 2 Clinical Trial
Oxford Brain Diagnostics has been selected to provide advanced MRI-based metrics for NeuroTherapia's Phase 2 trial of NTRX-07, a drug targeting neuroinflammation in Alzheimer's disease. Using Cortical Disarray Measurements, grey matter will be analysed to assess NTRX-07's potential in slowing disease progression, offering new hope for improving the lives of patients affected by this devastating condition.
OBD partners with Florida Memory Treatment Centers to investigate brain microstructure in Alzheimer's patients undergoing anti-amyloid therapy
As the global Alzheimer’s community enters a new era of drug treatments for Alzheimer’s patients, this research project aims to leverage Cortical Disarray Measurement (CDM®) to assess brain regions impacted by neurodegenerative conditions and quantify the extent of neurodegeneration as measured by the cortical microstructure. This study will examine cognitively impaired subjects receiving anti-amyloid treatment, uncovering the critical role of cortical microstructure in clinical settings.
OBD at the AAIC Advancements in Japan: Modernizing Diagnosis
Exciting news from the AAIC Advancements conference! Dr. Takashi Nakajima from the National Hospital Organization Niigata National Hospital presented our latest research on "Cortical Microstructure in Alzheimer's Patients Treated with Lecanemab – Preliminary Update on an Ongoing Real-World Observational Study." The poster highlighted early findings on the effects of Lecanemab on brain structure in Alzheimer's patients, using cortical disarray measurements (CDM) to assess microstructural changes. We were also honored to have Professor Takeshi Iwatsubo from the University of Tokyo visit our poster.
OBD will be attending AAIC 2024 in Philadelphia
Dr Steven Chance, Omar Ehsan, Mario Torso and Helena Mistry, will be attending AAIC 2024 in Philadelphia. The scientific sessions always deliver and updates on key drug trials will no doubt capture everyone's attention. We are presenting our posters on some hot topics and we cannot wait to showcase the results with you all at the right time. Huge thanks to our collaborators. 30th July Poster no. 481, Impact of TDP-43 co-pathology on limbic cortical microstructure in Alzheimer's disease: evidence from an autopsy-confirmed cohort with in-vivo diffusion MRI. 31st July Poster no. 392, Detection of presymptomatic cerebral amyloid angiopathy, CAA, using diffusion MRI analysis of cortical grey matter in hereditary mutation carriers.
